This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q91771060
rdf:type
wikibase:Item
schema:description
scientific article published on 07 July 2019 artículu científicu espublizáu en xunetu de 2019 wetenschappelijk artikel наукова стаття, опублікована 7 липня 2019 գիտական հոդված հրատարակված 2019 թվականի հուլիսի 7-ին
p:P577
wds:Q91771060-5E3A8743-216E-431C-BAA1-36F2CA2D2663
wdt:P577
2019-07-07T00:00:00Z
p:P2093
wds:Q91771060-B25D2EDB-CDC9-46BD-8E3D-B0365103BAD1 wds:Q91771060-89D0FF46-DC9C-4B48-BD26-2ADF81757775 wds:Q91771060-4A2363B7-74C1-49F5-ABBF-B924EE4DDB90 wds:Q91771060-0DF0917E-255D-4259-8932-16B0508DF9F9
wdt:P2093
Miquel Blasco Ming-Hui Zhao Andreas Kronbichler David Jayne
rdfs:label
ANCA associated vasculitis: The journey to complement-targeted therapies ANCA associated vasculitis: The journey to complement-targeted therapies
skos:prefLabel
ANCA associated vasculitis: The journey to complement-targeted therapies ANCA associated vasculitis: The journey to complement-targeted therapies
schema:name
ANCA associated vasculitis: The journey to complement-targeted therapies ANCA associated vasculitis: The journey to complement-targeted therapies
p:P50
wds:Q91771060-3F5B3C0C-9C68-4EFC-8DB3-F2715F7D605C
wdt:P50
wd:Q56447069
p:P1476
wds:Q91771060-F5A264E7-C776-4ACB-82C8-D5792CA08A39
wdt:P1476
ANCA associated vasculitis: The journey to complement-targeted therapies
p:P304
wds:Q91771060-981C40F0-0FCE-45B5-A180-F278523BB558
wdt:P304
394-398
p:P31
wds:Q91771060-F617AF51-6C9A-4A9D-B0C1-2360F92E7673 wds:Q91771060-8babee61-bb40-45c9-bdea-d874bfeb851b
wdt:P31
wd:Q7318358 wd:Q13442814
p:P698
wds:Q91771060-EACA62ED-1931-40B6-934D-1EC32FF25915
wdtn:P698
n7:31291610
wdt:P698
31291610
p:P1433
wds:Q91771060-9A7B009F-C644-416C-AECE-E560C948D10B
wdt:P1433
wd:Q6895954
p:P478
wds:Q91771060-6EC517C6-A5A5-404C-B061-5A3CEEC6DE53
wdt:P478
112
p:P356
wds:Q91771060-1CD40580-376D-4EBB-9854-DD732EBDB432
wdtn:P356
n12:J.MOLIMM.2019.06.018
wdt:P356
10.1016/J.MOLIMM.2019.06.018